Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves’ disease in a Polish population: association and gene dose‐dependent correlation with age of onset

Abstract

We replicated the association between Graves' disease and PTPN22 'T' reported in British Caucasians. We also found a gene dose-dependent effect of PTPN22 'T' on the age of onset of Graves' disease.

Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue

“…The highest T allele frequency (17.5%) was reported in northeast Russia, 14 followed by Finland (15.4%), 15 Ukraine (14.1%) 16 and Estonia (13.9%). 17 The frequency decreased toward the west, showing 11-13% in Poland, [18][19][20] 10-12% in Sweden, [21][22][23] Norway [24][25][26] and Germany, 24,[27][28][29] 11.7% in Croatia, 10-11% in the Czech Republic, 30,31 10.7% in Slovakia, 32 9.2% in Denmark, 33 and 8-10% in the UK [34][35][36][37][38][39] and the Netherlands. 24,[40][41][42] The decrease in the frequency toward the south was dramatic, with 7.75% in Hungary, 43 7.23% in Belgium, 7-8% in France, 44,45 5-7% in Spain 46-48 and 4.1% in Romania.…”

“…All three case-control studies recruited for this meta-analysis showed a significant association between PTPN22 C1858T and Graves' disease with ORs ranging from 1.43 to1.88. 5,20,109 Meta-analysis showed a strong association between the T allele and Graves' disease (OR ¼ 1.59; 95% CI ¼ 1.37-1.85,…”

The role of common genetic markers in susceptibility to type 1 diabetes and autoimmune thyroid diseases

“…Группой ученых из разных стран была доказана связь ва-рианта R620W гена PTPN22 с ДТЗ [100,101] и АИТ [102], хотя связь с АИТ была не столь убедительной [103], как с ДТЗ. В ис-следовании Skorka с соавт.…”

Association of Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) C1858T gene polymorphism with susceptibility to autoimmune thyroid diseases: a meta-analysis

“…Via an extensive search, eleven eligible articles [3,7,[16][17][18][19][20][21][22][23][24] were selected for this meta-analysis, including 3764 AITD cases and 3328 controls. Study characteristics were summarized in Table 1.…”